MAM
DD invites short films on Govt schemes, ‘DAVP producers’ preferred
NEW DELHI: Doordarshan has invited proposals from experienced producers for five Hindi documentaries on five different programmes of the incumbent government.
The proposals for films with maximum duration of 24 minutes have to be submitted by 24 April 2017. They should also be accompanied by a shorter version of three minutes. The aim of the films will be to showcase success stories in all the five programmes.
The five programmes to be covered are Saugmya Bharat – Accessible India Campaign of the Social Justice Ministry, Swachh Bharat Mission of the Drinking Water and Sanitation Ministry, Sabka Saath Sabka Vikaas of the Minority Affairs Ministry, Mission Indradhanush of the Health Ministry, and Pradhan Mantri Fasal Bima Yojana including the Soil Health Card of the Agriculture Ministry.
Preference will be given to producers empanelled with the Directorate of Advertising and Visual Publicity but the producer shall not be a defaulter with DAVP or Doordarshan at the time of submission of proposal.
The producer must have produced for any broadcaster at least 24 hours of factual documentaries in any Indian language in the last three financial years. The producer should have an annual turnover of a minimum Rs 10 million in each of the last three financial years.
Also read: Parliamentary panel pans DD, AIR for recurring lapses
Govt denies cartelisation in Prasar Bharati, 724 complaints against MIB in ’16
DD ad budget crosses Rs 33 million at fag end of 2016-17
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
